Biomarkers Utility for Sepsis Patients Management by Iskandar, Agustin et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 4
Biomarkers Utility for Sepsis Patients Management
Agustin Iskandar, Hani Susianti,
Muhammad Anshory and Salvatore Di Somma
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.76107
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original work is properly cited. 
sti  Is r, i  si ti, 
       
iti l i f r ti  i  il l  t t   f t  t r
Abstract
Sepsis is a global problem in either developing or developed countries and it is expected 
that the number of patients with sepsis and septic shock will tremendously increase in 
next decades also because of the antibiotic resistance growing issue worldwide. Criteria 
for sepsis diagnosis and prognosis have been recently established, but still a further 
understanding of the role of biomarkers in this setting is needed. Better utilization of 
biomarkers such as white blood cell count, CRP, lactate, procalcitonin, presepsin and 
bioadrenomedullin in sepsis patients, a state of the art on how to use them is needed. This 
review will focus on the actual recognized role of sepsis biomarkers not only for diagno-
sis purpose but also to improve patients treatment results in order to reduce mortality, 
hospital length of stay and cost related.
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1. Introduction
For about a century, sepsis has been defined as a systemic inflammatory response of the host 
to an infection. The lack of precise definitions and diagnostic criteria had also made difficult or 
even impossible to compare different studies and research. It was necessary to find a precise 
and standardized definition of sepsis, a common nomenclature to correctly diagnose the disease, 
allowing the creation of a targeted therapy for the patient [1]. The SIRS criteria were considered 
too sensitive and unspecific to be used in the identification of sepsis in most clinical practice [1, 2]. 
This scheme is based on four specific characteristics defined by the acronym PIRO:
• Predisposition, indicates pre-existing conditions potentially able to reduce septic patient 
survival;
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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Sepsis
Documented or suspected infection.
Pathological process caused by the invasion of tissues, fluids or cavities of the host normally sterile by pathogenic or 
potentially pathogenic microorganisms, associated with some of the following signs and symptoms:
Variables:
1. Temperature > 38.3°C or < 36°C.
2. Heart rate > 90 min−1 or > 2 SD above the normal value for age.
3. Tachypnea.
4. Alteration of the state of consciousness.
5. Important edema or positive fluid balance (>20 mL/kg in 24 h).
6. Hyperglycaemia (>120 mg/dL) in the absence of diabetes.
- Inflammatory variables:
1. White blood cells >12,000 mL−1 or < 4000 mL−1.
2. White blood cells in the standard but >10% of immature forms.
3. C-reactive protein>2 SD normal values.
4. Procalcitonin>2SD normal values.
- Hemodinamic variables:
1. Arterial hypotension (SBP <90 mmHg, MAP <70 mmHg, or a reduction in SBP > 40 mmHg in adults or < 2 SD 
below normal for age).
2. SvO2 > 70%.
3. Cardiac Index>3.5 L min−1 m2.
- Organ defunction variables:
1. Hypoxemia (PaO2/FiO2 < 300).
2. Acute oliguria (<0.5 mL/kg/h).
3. Increase of creatinine>0.5 mg/dL.
4. Abnormality of coagulation (INR > 1.5 or APTT>60 s).
5. Ileus (absence of peristalsis).
6. Platelet decrease (<100,000 mL−1).
7. Hyperbilirubinemia (> 4 mg/dL).
- Tissue perfusion variables:
1. Hyperlactacidemia (> 1 mmol/L).
Severe sepsis
Sepsis associated with organ dysfunction (hypotension, hypoxemia, oliguria, metabolic acidosis and 
thrombocytopenia).
Septic shock
Severe sepsis with hypotension despite adequate fluid rehydration, along with the presence of organ perfusion 
abnormalities.
Table 1. SCCM/ESICM/ACCP/ATS/SIS – 2001 [3].
• Insult or infection, reflects the pathogenicity of the microorganism;
• Response of the organism to the infectious event, including the manifestation of the SIRS;
• Organ dysfunction, which includes both organ failure and the failure of the coagulation 
system.
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The use of this scheme is useful for defining, diagnosing and treating patients with sepsis but 
above all for obtaining better results in situations of severe sepsis and septic shock. The PIRO 
model is not yet fully defined and it has been debated [2]. Table 1 summarizes the different 
definitions obtained after the two Consensus Conferences [3]:
Therefore, given the need to reexamine the current definitions, the “European Society of 
Intensive Care Medicine” and the “Society of Critical Care Medicine” have organized a task 
force of 19 specialists among infectiologists, surgeons, pulmonologists and anesthesiologists 
in order to review the data in the literature so far available.
Although SIRS criteria may be useful in the general diagnosis of an infection, they represen-
tative of an appropriate adaptive response of the organism, while sepsis involves an organ 
dysfunction that underlies a much more complex pathology; in this context the pro- and anti-
inflammatory endogenous factors play a fundamental role and they are responsible for the 
inter-individual differences between patients [4–6].
The task force therefore suggests to use new values to decide to further investigate the search for 
organ dysfunction damage, to initiate or modify a therapy that is more appropriate and to con-
sider patient’s hospitalization in an Intensive Care [7]. Table 2 reflects the conclusions reached 
by the task force and the implications in everyday practice, with the exemplification of the new 
diagnostic criteria and the new classification recognized by the International Classification of 
Diseases (ICD) [7].
Current guidelines and 
terminology
Sepsis Septic shock
1991 and 2001 consensus 
terminology
Severe sepsis
Sepsis-induced hypoperfusion
Septic shock
2015 definition Sepsis is life-threatening 
organ dysfunction caused by a 
dysregulated host response to 
infection
Septic shock is a subset of sepsis in which 
underlying circulatory and cellular/metabolic 
abnormalities are profound enough to 
substantially increase mortality
2015 clinical criteria Suspected or documented infection 
and an acute increase of ≥2 
SOFA points (a proxy for organ 
dysfunction)
Sepsis and vasopressor therapy needed to 
elevate MAP ≥65 mmHg and lactate >2 mmol/L 
(18 mg/dL) despite adequate fluid resuscitation
Recommended primary ICD codes
ICD-9 995.92 785.52
ICD-10 R65.20 R65.21
Framework for 
implementation for coding 
and research
Identify suspected infection by using concomitant orders for blood cultures and 
antibiotic (oral or parenteral) in a specified period
Within specified period around suspected infection:
1. Identify sepsis by using a clinical criterion for life-threatening organ dysfunction
2. Assess for shock criteria, using administration of vasopressors, MAP <65 mmHg 
and lactate >2 mmol/L (18 mg/dL)
Table 2. Terminology and International Classification of Disease coding [7].
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2. Sepsis in emergency department
Sepsis is a complex clinical syndrome that still represents a major challenge for today’s medi-
cine. In fact, despite the current possibilities of treatment, sepsis remains burdened by a high 
prevalence in the population and above all by a severe prognosis, representing one of the 
pathologies with the highest rate of morbidity and mortality. It is responsible for about one-
third of all hospital admissions, and about 50% of ICU admissions. Mortality would reach 
40%, of which 25% of deaths would occur within 48 h of entry into ICU [8].
In this complex scenario, the emergency doctor plays a key role. In fact, it depends on 
early diagnosis and treatment, the two factors that are recognized today as fundamental 
in the correct management of the septic patient as it is able to improve the prognosis. The 
enigmatic and often heterogeneous nature of sepsis, the absence of specific clinical and 
laboratory elements causes the lack of valid diagnostic tools, strongly influencing early 
intervention [9].
The recent literature has therefore placed great attention in the search for all clinical and 
laboratory factors, which can help in the rapid identification of sepsis and in the stratifica-
tion of the risk of such patients, in order to make the treatment as aggressive as possible in 
terms of timeliness and effectiveness. More than two decades ago, sepsis was defined by 
the combination of an SIRS and an infection. This criterion, therefore useful for the correct 
diagnosis of sepsis, is also endowed with prognostic capacity, proving to be effective for the 
gravity stratification of patients with suspected infection due to the linking of these criteria 
with the presence of organ damage. However, the role of SIRS has been recently revised 
because although it has high prognostic power, it has little specificity being involved in a 
wide variety of pathologies regardless the presence of infection, in which the differential 
diagnosis often becomes difficult. Furthermore, it has been calculated that a certain num-
ber of patients with sepsis may not present SIRS criteria (about 1 in 8) [10]. The “Third 
International Consensus Definitions for Sepsis and Septic Shock” (Sepsis-3) [7] has therefore 
decided to go beyond the concept of SIRS, emphasizing rather the role of the organism’s 
response to infection and organ damage (identified by a SOFA value ≥2) in the pathogenesis 
of sepsis.
3. Diagnosis
Sepsis diagnosis is established on the basis of patient’s symptoms and clinical signs combined 
with radiological examinations and laboratory tests such as the search for biomarkers and 
identification of the microorganism responsible for the infection. In cases of sepsis, delay in 
diagnosis and antibiotic therapy affects the mortality of critically ill patients. Establishing diag-
nosis and therapy is very important but to hinder their definition it is difficult in differentiating 
sepsis from non-infectious stimuli in SIRS situations, symptoms and clinical signs, radiologi-
cal and laboratory tests used for the diagnosis of sepsis are those reported in the previously 
reported tables, used in the definition of sepsis itself. The use of clinical scores, blood cultures 
and biomarkers for the diagnosis of sepsis will be discussed later.
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4. Clinical scores
Since 2004, worldwide, the “Surviving Sepsis Campaign”, consisting of a multidisciplinary 
team of specialists, periodically deals with the preparation and updating of documents on the 
general management of the septic patient and some specific aspects, such as timing and the 
optimal choice of antibiotic therapy, blood pressure support, glycemic control and oxygen-
ation. In particular, at the last revision, the bundle of measures are implemented within the 
first hours after admission of the patient to reduce mortality was well defined [11].
At the same time, over the years, the need arose, especially in an intensivist environment, 
to identify those factors capable of predicting clinical severity and, in particular, the risk of 
death; for this purpose, many patient severity scores have been proposed and validated, use-
ful from the moment of diagnosis to stratify the patient’s clinical severity and, indirectly, to 
assess the risk of mortality [12].
The ideal prognostic score should have high sensitivity and high predictive value, be able 
to predict early mortality or clinical evolution, be rapidly usable, available everywhere, eco-
nomic, objective and non-observer-dependent. Currently, no clinical score has all these char-
acteristics. In particular, the two basic requirements of a prognostic system are the power of 
discrimination and calibration [13].
There are several works that have evaluated in the emergency medicine settings, the appli-
cability of different gravity scores. In particular, simpler models to be calculated than those 
commonly used in Intensive Care Unit (ICU) have been proposed [11]. In 2003, Shapiro 
et al. have proposed the adoption of a new prognostic model, called Mortality in Emergency 
Department Sepsis (MEDS), as a method for stratifying patients afferent in emergency medi-
cine with suspected sepsis [14]. Sankoff et al. resumed the MEDS score and carried out a 
multi-center prospective study to verify its reproducibility and validity [15]. The MEDS is the 
only score designed to be used in the septic patient in settings different from ICU. Numerous 
prognostic models born to be used in ICU were subsequently applied in different care set-
tings, primarily in emergency medicine.
In one of the best known studies, Jones et al. have proposed the adoption of the Sequential 
Organ Failure Assessment (SOFA) score as a tool to predict the outcome of patients with 
severe sepsis with signs of hypoperfusion or septic shock. The authors considered all patients 
over the age of 18 with sepsis and evidence of hypoperfusion (systolic BP <90 mmHg or lac-
tate levels>4 mmol/L); calculated the SOFA score at time zero and after 72 h (delta SOFA). The 
outcome of the study was to evaluate in-hospital mortality, the possible correlation between 
the difference in SOFA between admission and after 72 h, and finally mortality. The authors 
have shown a good correlation between the SOFA score at the entrance and the delta SOFA 
with the risk of in-hospital mortality. The limit of the work, similar to the studies on the 
MEDS score, is that it is an experience conducted only in a single center, which should be 
validated and extended to several centers to obtain a useful risk assessment tool [16, 17]. Alan 
E Jones et al. also demonstrated the usefulness of SOFA as a predictive prognosis score in 
patients with sepsis, and in particular in patients with severe sepsis with signs of hypoperfu-
sion already on arrival in the emergency room [16].
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The SOFA score (Table 3) is therefore a prognostic score, used for the prediction of mortality, 
based on the degree of dysfunction of six different systems and apparatuses, involved in the 
pathophysiology of the sepsis response. In particular, the respiratory, cardiovascular, renal, 
neurological, coagulative and hepatic systems are examined. The alteration of each of them 
indicates a condition of particular gravity, and the progression of the number of systems 
involved represents a negative prognostic variable. Thus, values < 9 predict mortality <33%, 
values between 9 and 11 a mortality of 40–50% and values>11 of 95%. Only one work assessed 
the accuracy of different prognostic models in septic patient assessment in a care setting of this 
kind [18]. The study, conducted in a single center, evaluated five different prognostic models 
MEDS, APACHE II, SAPS II, SOFA score (at time 0 and 24 h) and the Charlson index. The 
outcome examined was 28-day mortality, the number of patients examined was 140. The most 
accurate result was the 24-hour SOFA; however, also the SOFA at time 0, the maximum SOFA 
and increasing values of SOFA were related to mortality. It is useful to underline that the 
patients enrolled in the study already had a diagnosis of sepsis-septic shock with a mortality 
equal to 29%, much higher than the previously reported jobs (close to that of the IT depart-
ments). It is therefore reasonable to think that for a population of this kind, the use of a score 
System Score
0 1 2 3 4
Respiration
PaO
2
/FiO
2
, mmHg 
(kPa)
≥400 (53.3) <400 (53.3) <300 (40) <200 (26.7) with 
respiratory support
<100 (13.3) with 
respiratory support
Coagulation
Platelets, ×103/uL ≥150 <150 <100 <50 <20
Liver
Bilirubin, mg/dL 
(umol/L)
<1.2 (20) 1.2–1.9 (20–32) 2.0–5.9 
(33–101)
6.0–11.9 (102–204) >12 (204)
Cardiovascular MAP 
≥70 mmHg
MAP 
<70 mmHg
Dopamine <5 
or dobutamine 
(any dose)b
Dopamine 5.1–15 or 
epinephrine ≤0.1 or 
norepinephrine ≤0.1b
Dopamine >15 or 
epinephrine >0.1 or 
norepinephrine >0.1b
Central nervous 
system
Glasgow Coma 
Scale scoreb
15 13–14 10–12 6–9 <6
Renal
Creatinine, mg/dL 
(umol/L)
<1.2 (110) 1.2–1.9 
(110–170)
2.0–3.4 
(171–299)
3.5–4.9 (300–440) >5.0 (440)
Urine output, mL/d <500 <200
Abbreviations: FiO
2
: fraction of inspired oxygen; MAP: mean arterial pressure; PaO
2
: partial pressure of oxygen.
aCatecholamine doses are given as ug/kg/min for at least 1 h.
bGlasgow Coma Scale scores range from 3 to 15; higher score indicates better neurological function.
Table 3. Sequential (sepsis-related) organ failure assessment score [7].
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validated in ICU (such as SOFA) may be more reliable than models validated in emergency 
medicine (such as MEDS) .
The shorter version of SOFA score, the qSOFA, evaluates only three clinical variables that 
are easily obtainable “bedside” which are systolic arterial pressure ≤ 100 mmHg, respiratory 
rate ≥ 22 times/min and alteration of the mental state (GCS ≤ 13 or other alteration). A ≥ 2 
qSOFA would allow rapid detection of the septic patient and would be associated with 10% 
mortality. However, recent scientific studies have questioned the role of qSOFA, comparing 
it with the previous SIRS diagnostic criteria. In particular, a qSOFA ≥2 would seem to have 
high specificity but low sensitivity compared to a SIRS ≥2 value in the recognition of organ 
damage, and this could limit its use as a screening method [9].
5. Blood cultures
Blood culture is the “gold standard” exam to diagnose sepsis because it allows the etiologi-
cal agent to be determined and provides the clinician with useful information for targeted 
therapy [11].
Several factors can influence the effectiveness and clinical significance of blood culture. In the 
pre-analytical phase, the withdrawal methods and the number of samples are very important. 
The sampling must be done when the first suspicions of infection arise and above all before the 
administration of any antibiotic, otherwise the therapy should be discontinued for a few hours or 
taken before the next administration of the antibiotic. In most episodes of bacteremia, it is neces-
sary to collect two or three blood culture sets within 24 h to identify the pathogen, in case a single 
sample set is taken the probability of not identifying a patient with sepsis is about 35–40% [19].
An important factor for the accuracy of the diagnosis is the volume of blood present in the 
blood culture flask, in fact it is necessary to inoculate at least three colony forming units (CFU) 
per milliliter to get 100% positive; however, it is considered that in adult patients, in sepsis, 
the concentration per milliliter of blood is normally 0.1–1 CFU/mL, while in pediatric age the 
bacterial load is equal to 10–100 CFU/mL [20, 21].
Therefore, in the adult, the ideal amount of blood will therefore be 5–10 mL per vial and for 
pediatric patients of 1–5 mL. The ratio between the volume of the sample and that of the cul-
ture broth must allow the growth of many microorganisms, this ratio is 1:5–1:10 even if with 
the addition of substances that disable the inhibitory factors the optimal ratio is 1:5 [22–24]. 
Another important factor for a successful blood culture is incubation time.
The Clinical and Laboratory Standards Institute (CLSI) established that 5 days of incubation 
are sufficient to detect 95% growth of clinically significant bacteria (CLSI, 2007). Several stud-
ies have shown that in 97.5% of blood cultures containing a pathogen are positive after 3 days 
using automated systems [25, 26].
In the case of suspected endocarditis supported by demanding bacteria, or yeast septicemia or 
in pediatric patients, the incubation times are prolonged. Moreover, a possible administration 
of a therapy prior to sampling or the presence of a pathogen with particular nutritional needs 
lowers the ability of the investigation to identify the microorganism, in fact it has been shown 
that the levels of analytical sensitivity vary between 8 and 88% [27].
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A limitation of blood culture is the lack of sensitivity in the search for particular bacteria that 
are often responsible for community-acquired pneumonia, such as Mycoplasma pneumoniae, 
Legionella pneumophila and Chlamydia pneumoniae and other germs that are difficult to grow 
or even non-cultivable such as Coxiella burnetii, Francisella tularensis, Bartonella spp., Rickettsia 
spp. and Nocardia spp. [28, 29].
The value of blood culture as a diagnostic test for bacteraemia and sepsis is limited, in fact, 
it emerges that in 50% of cases, the blood culture is negative even if the diagnosis of sepsis is 
certain and also the first results are provided after 48 h to conclude analysis with the identifi-
cation and sensitivity to the pathogen’s antibiotics after 5 days or more [1, 30, 31].
6. Sepsis biomarkers
6.1. Introduction
The current gold standard for the diagnosis of infections of the circulatory stream is blood 
culture, unfortunately its important limitation is the time necessary to complete the survey 
that goes from 1 to 5 or more days in the case of suspected sepsis caused by yeasts. The 
ideal situation would be to analyze the patient’s on-site blood and provide all the necessary 
information to immediately target a targeted antibiotic therapy, and then the test should 
provide data for therapy evaluation by measuring the clearance of pathogenic nucleic acids 
in the blood in a certain period of time.
The ideal molecular test does not exist but these characteristics will have to be set as a long-
term objective in the design of new molecular techniques for the diagnosis of sepsis.
A short-term objective is to analyze blood in parallel to culture methods and identify pathogens 
responsible for infection including non-cultivable organisms, and also to detect some of the deter-
minants of drug resistance [30]. The molecular techniques currently available on the market can 
be distinguished in those based on the principle of amplification of the bacterial and/or fungal 
genome and those that exploit the principle of hybridization. Blood culture coupled with molecu-
lar investigations involves some disadvantages inherent to the traditional method such as delay in 
response with its possible alteration due to an unsuitable collection and the inability to provide the 
nutrients necessary for the development of demanding microorganisms. In the market, there are 
several kits in molecular biology that identify the pathogen from positive blood culture samples.
In the medical field, a circulating biochemical marker is defined as a demonstrable, therefore 
measurable, substance in the blood whose variation in concentration constitutes the signal of 
the presence of a pathology [32].
Regarding the role of biomarkers in the management of sepsis, over time various molecules 
were analyzed that, taken singly or combined in a panel, could be able to allow rapid diag-
nosis and prognosis, and that in the near future could also be able to guide the therapy itself 
to improve the clinical response and management of these patients [33]. Among the vari-
ous biomarkers, some are used daily in clinical practice. Among these great importance has 
always been attributed to the role of lactates. They are considered useful by the guidelines 
because they have a prognostic value, being related to disease severity especially for values 
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≥ 2 mmol/L. However, according to other authors, the additive prognostic role of lactates to 
qSOFA would not be significant [34].
CRP and PCT are routinely used in patients with suspected first aid infection. CRP, released 
as an acute phase protein in inflammatory states, has a high specificity but low sensitivity and 
is therefore used for its negative predictive value. PCT, on the other hand, has been shown to 
have diagnostic and prognostic value in the management of sepsis. It is released in the course 
of bacterial infections, being therefore aids in the differential diagnosis, and is also included 
within the guidelines as a valid aid in guiding antibiotic therapy, representing a “mirror” of 
the therapeutic response to infection, and for its high prognostic power.
More recently, however, we have focused on the role of adrenomedullin (ADM). It is a pep-
tide that several studies have shown to increase in septic patients [35]. The secretion mecha-
nism depends to a large extent on stimulation by the lipopolysaccharide of bacteria, and its 
plasma levels derive mainly from secretion by endothelial cells [36]. ADM plays a funda-
mental role in hyperdynamic response during the early stages of sepsis and its main func-
tion is vasodilator [37]. After demonstrating the prognostic role of its precursor MR-proADM 
[38], thanks to a novel instrument based on a chemiluminescent sandwich detection (in 
which specific monoclonal antibodies are used against the C-terminal part of the peptide), 
today, it is possible directly measure the biologically active molecule (Bio-ADM or ADM). 
Thus, in a study published in 2014, our group showed that ADM values are significantly 
higher in patients with severe sepsis and septic shock than those with sepsis [39]; in par-
ticular, ADM, considered one of the most potent endogenous vasodilators, was found to be 
closely related to low mean arterial pressure (PAM) values and to the need to use vasopres-
sors, thus detecting septic shock markers. Furthermore, higher values have been correlated 
with greater probability of death; and finally, the detection of multi-stroke ADM has proved 
to be fundamental in identifying patients with a worse prognosis [39].
From what has emerged, considering that sepsis determines endothelial dysregulation, excessive 
vasodilatation and consecutively collapse of arterial pressure and micro-vascular homeostasis 
and that ADM has as its main function vasodilator and therefore regulator of vascular tone, new 
studies currently in progress and still in the experimental phase, are directed to the development 
of a murine anti-ADM monoclonal antibody (HAM1101) that can become a therapy in septic 
shock, according to the hypothesis that it can improve the hemodynamics and perfusion of the 
organs and, consequently, also reduce the incidence of acute renal failure. To date, a humanized 
antibody has been selected, the HAM8101, which will be the subject of phase III experimental 
studies in the near future [39, 40].
Establishing diagnosis and therapy is very important but to hinder their definition is the dif-
ficulty in differentiating sepsis from non-infectious stimuli in SIRS situations, especially in those 
critically ill patients who may have developed SIRS for other causes such as pancreatitis, trauma, 
burns, etc. Therefore, the detection of an accurate biomarker in sepsis is decisive in critical situa-
tions with the ability to exclude or confirm an acute bacterial infection, to evaluate the systemic 
inflammatory response to infection and the host response to the established therapy [41].
An ideal biological marker must have different characteristics:
• useful in early diagnosis, provide information for a definitive diagnosis or help to identify 
a probable diagnosis;
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• provide information regarding the prognosis including the patient in subpopulations 
whose outcome is better/worse than the population in question;
• provide, in the clinical course, useful information on how the patient responds to therapy 
and eventually help in modulating the therapeutic strategy;
• high specificity and sensitivity;
• have a clinically useful half-life time;
• be easily determinable and reproducible and difficult to influence by disturbing factors;
• have low costs and be easily used to quantify intervention actions, costs and benefits;
• in the case of sepsis, allow differential diagnosis between infectious and non-infectious 
etiology.
The use of biomarkers must always be integrated with the information deriving from a careful 
medical history collection, from a complete clinical objective examination, from the results of 
laboratory analyzes and diagnostic methods required in different cases. In fact, only the set of 
all these elements make it possible to reduce the number of evaluation errors deriving from 
a hasty decision, often dictated by superficiality or by incorrect knowledge. At present, there 
is no biomarker that ensures 100% correlation with a single pathology. In fact, we speak of 
“highly significant values” for a given pathological condition. Other potential uses of biomark-
ers include their prognostic role and, consequently, the ability to drive antibiotic therapy and 
to evaluate the response to the therapy itself, identifying those patients who most likely will 
face complications and organ dysfunction [32].
In the literature, there are many biomarkers already evaluated, such biomarkers for chemo-
kine, cellular, receptor, hemostasis and vascular and others [42].
The available markers for the diagnosis of sepsis are numerous. There are leukocyte count, 
C-reactive protein (CRP), procalcitonin (PCT), endotoxin, cytokine, IL-1 receptor, comple-
ment factors, endothelin-1, ICAM-1 and VCAM-1, fosofolipase A2, PGE2, lactoferrin, neop-
terin, elastase, different interleukins (ILS), adrenomedullin (ADM) and proADM, atrial 
natriuretic peptide (ANP) and proANP, pro-vasopressin (copeptin), interferon-γ (IFN-γ), 
triggering receptor expressed on myeloid cells 1 (TREM-1) and resistin [41–44]. In several 
recently published studies, the most relevant biomarkers used, as they have a high diagnostic 
and prognostic capacity are CRP [45], PCT [46], ADM [47], copeptin [48], natriuretic peptide 
(MR-proANP) [49], presepsin (or CD 14 ligand) [50] and suPAR [51].
Unfortunately, in the sepsis, an ideal marker has not yet been identified and those normally 
used (fever, leukocytosis, CRP, PCT, etc.) often have little sensitivity and specificity, conse-
quently they have limited use in patient management. Their dosage should be used and eval-
uated in the context of the clinical situation in which the patient is located and therefore it is 
essential to determine the appropriateness of the individual markers’ request in collaboration 
with the clinician to exploit their potential to the full diagnostics, therapeutic monitoring and 
prognosis.
This section will discuss about white blood cell count (WBC), serum lactate, C-reactive pro-
tein (CRP), procalcitonin (PCT), presepsin and bioadrenomedullin as biomarker of sepsis.
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6.2. White blood cell count (WBC)
White blood cell is a part of innate immune response by localizing infection. Otherwise in 
systemic sepsis process, there is profound leucocyte activation. Systemic sepsis also leading 
to organ damage and organ dysfunction attenuated by inhibition of leukocyte-endothelial 
interactions, systemic leukocyte activation and disseminated leukocyte adhesion [52].
The WBC results were considered abnormal if both the total number of neutrophils and the 
immature/total neutrophil ratio were abnormal simultaneously [53]. The sensitivity and 
specificity WBC for sepsis diagnosis in the literature vary widely, since there are significant 
differences in definitions used to count total neutrophils and sub-fractions; with sensitivity 
varying from 17 to 100% and specificity from 31 to 100%. A study by Caldas et al., reported 
that combination of WBC and CRP had sensitivity better than WBC alone [54].
In 2001, Zahorec introduced the use of neutrophil and lymphocyte count ratio (NLCR) as one 
of infection marker [55]. There is also correlation between NLCR and disease severity, also 
predictor for bacteremia [56].
The sepsis criteria recently changed from Sepsis-2 to Sepsis-3 highlighting on life-threatening 
organ damage caused by dysregulated host response to infection. This also affecting the use 
of biomarker in the diagnosis of sepsis, based on Ljungstrom et al., the AUC of NLCR to pre-
dict positive culture was 0.71, similar to previous study by Loonen showed AUC of 0.73 and 
0.77 [56–58].
6.3. Serum lactate
Lactate is an important source of energy, particularly during starvation. Lactate also contributes 
to acidic environment by converting to lactic acid. Lactate value of 1400–1500 mmol/L per day 
resulted from anaerobic glycolysis activity as the reduction of pyruvate, moreover in tissue 
hypoxia [59]. Excretion of lactate mostly occurs in liver (60%) followed by kidney (30%) and 
other organs [60]. Shock status, such as cardiogenic or septic shock, is an important source of 
lactate production. The mortality rate was 46.1% for patients with both hypotension and lactate 
≥4 mmol/L, 36.7% for septic patients with hypotension alone and 30% for patients with lactate 
≥4 mmol/L alone [61, 62].
According to the new definition, septic shock can be diagnosed under two circumstances. 
The first one is persistent hypotension and the second one is increase of lactate serum level 
for more than 2 mmol/L, with additional note that lactate cut off were changed from 4 to 
2 mmol/L. Therefore, increase of lactate serum level for more than 2 mmol/L can be recog-
nized as a sign of septic shock. This condition greatly affects by hypotension and the use of 
vasopressor which caused further tissue hypoxia [62].
Ljungstrom et al. showed lactate correlate well with Sepsis-2 criteria in diagnosis of sepsis 
and septic shock, with specificity, accuracy and DOR were 97, 92 and 56.3%, respectively, by 
using cutoff 3.5 mmol/L. The downside of lactate is that even lactate level alone is widely used 
for diagnosis in early sepsis, the elevated level is not considered specific for sepsis diagnosis, 
hence it is proven to be more valuable in predicting mortality. The suggestion is to use com-
bination of several biomarkers including lactate in diagnosing septic and septic shock [56].
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6.4. C-reactive protein (CRP)
C-reactive protein (CRP) is synthesized by the liver after the action of various inflammation 
mediators such as IL-1, IL-6 and IL-8. This biomarker is produced 4–6 h after the phlogistic 
stimulus, and doubles its concentration in the circulation within 8 h and reaches its peak in 
36–50 h [2, 63, 64].
CRP has both pro-inflammatory and anti-inflammatory characteristics, its half-life is 19 h and 
its levels in the blood stream remain elevated for a few days after the infection has disap-
peared [63]. Elevated plasma CRP levels indicate the presence of an infection and/or organ 
damage while protein synthesis will be significantly reduced in the case of hepatic failure [65]. 
The normal value of plasma CRP is <1 mg/dL, while it may increase up to 50 mg/dL in case 
of acute severe infection. The increase in CRP does not appear to be related to the severity of 
inflammation and also increases in cases of non-infectious diseases such as autoimmune dis-
eases, acute coronary syndromes, rheumatic disorders, malignant tumors and after traumas 
or surgical interventions [66].
In conclusion, the values of CRP do not allow to distinguish between sepsis and SIRS of a 
non-infectious nature. This marker appears to be more sensitive than parameters such as the 
leukocyte count and the temperature but less specific than others such as PCT. However, CRP 
is a commonly used low cost and widely available marker.
6.5. Procalcitonin (PCT)
“Procalcitonin” (PCT) is a protein consisting of 116 amino acids, with a molecular weight of 
approximately 13 kDalton. The amino acid sequence of PCT is identical to that of calcitonin 
prohormone; it comprises the sequence of calcitonin from position 60 to 91 (32 amino acids). 
Through specific proteolysis, PCT (116 amino acids) and, in healthy intracellular individuals, 
calcitonin (32 amino acids) are released from this protein. Currently, four genes correspond-
ing to calcitonin with homologies in the nucleotide sequence are known. These genes are all 
called “genetic family of calcitonin”, although not all of them produce the calcitonin peptide 
hormone. The “CALC-I” gene, a candidate responsible for the production of procalcitonin 
induced by the inflammatory state, is one of the first examples of a process called “alternative 
splicing”. The primary transcript can give rise to different mRNAs for inclusion or exclusion 
of the different exons present. Calcitonin encoding mRNA is the main product of CALC-I 
transcription in thyroid C cells, whereas CGRP-I mRNA (CGRP = calcitonin gene-related pep-
tide) is produced in the nervous tissue of the central and peripheral nervous system (115). The 
plasma concentrations of procalcitonin in healthy individuals are very low, on the order of 
picograms, and in any case below the limits of determination of the test used for the immu-
noluminometric assay (<0.1 ng/mL, LUMItest PCT, BRAHMS Diagnostica, Berlin). PCT is 
a very stable protein in vivo and in vitro. In plasma it does not degrade to active calcitonin 
hormone; its in vivo half-life time is approximately 25–30 h [67] [115]. PCT production was 
stimulated in healthy volunteers through the intravenous injection of small amounts of bacte-
rial endotoxin (lipopolysaccharide). PCT can be observed in the plasma 2 h after endotoxin 
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injection; between 6 and 8 h after the concentration of PCT increases rapidly up to a plateau 
about 12 h after injection. Over the next 2–3 days, the PCT values decrease until they reach 
their normal value [67, 68].
PCT concentrations above 0.5 ng/mL always indicate an acute infection or inflammation, with 
particularly high values in patients with severe bacterial infections in the acute phase and 
with septic inflammation. Plasma PCT concentration in the presence of serious infections and 
sepsis; however, can vary from 1 to 1000 ng/mL and PCT, in these cases, is probably not pro-
duced by C cells of the thyroid, but is inclined to believe that origin from neuroendocrine cells 
of the lung or intestine [67].
The release of PCT is determined only by the systemic reaction of the organism toward the 
infection, therefore local bacterial colonizations, encapsulated abscesses and localized and 
limited infections do not cause PCT release. In addition to bacterial infections, plasma PCT 
concentration has been shown to increase in acute forms of malaria and fungal infections. 
PCT, on the other hand, does not appear or appear to be not very significant, in the presence 
of viral infections, autoimmune diseases, neoplasia or traumatic surgery [69]. It could thus 
become one of the first-choice tests to be performed in patients with fever of unknown origin 
in the emergency room, to unmask an underlying bacterial infection [46, 70].
Bacterial endotoxins play the most important role in the mechanism of PCT release. At the end 
of the acute inflammatory reaction, the PCT concentration decreases according to the plasma 
half-life time. From these considerations it is clear that PCT, besides being a diagnostic marker 
of systemic bacterial infections, also has an important prognostic value. The medical litera-
ture, in fact, has shown the correlation between the severity of the clinical picture, the risk of 
development of multi-organ failure (MOF), long-term outcomes and one-year mortality, with 
plasma PCT values; in particular it was established that:
• high values of PCT protracted over time indicate an inflammation in progress;
• constantly increasing PCT levels are an unequivocal sign of poor prognosis;
• decreased PCT levels indicate favorable prognosis, improvement of inflammation or ad-
equate therapeutic treatment of infection.
PCT thus becomes essential for the identification of patients at greatest risk, for guiding their 
therapy and for monitoring them over time [69, 71].
The areas in which the PCT could be used are numerous. In addition to patients who come to 
the emergency room with fever or suspected sepsis, PCT has been evaluated as both diagnos-
tic [72, 73] and prognostic [74, 75] markers in pneumonia of bacterial origin. Even in this case, 
if associated with the clinical picture, the radiographic imaging and the values of the inflam-
matory indexes (CRP and white blood cells in particular), the PCT has shown to have a high 
predictive value as a biomarker. For the same reasons listed above, PCT should be measured 
in patients with significant dyspnea affected by COPD. The bacterial origin of exacerbations is 
often responsible for hospitalizations and mortality, and early intervention could reduce both 
of these two harmful consequences [76, 77].
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Finally, an increase in PCT has also been shown in bacterial endocarditis [78] and in acute cor-
onary syndromes [79, 80], while its prognostic use as a marker of infection has been exploited 
in the monitoring of patients undergoing major surgery [81].
Despite the wide space that scientific research has devoted to PCT, its exact mechanism of 
action still remains partially unknown. The rapid induction of PCT after administration of bac-
terial endotoxins and its relationship to cytokines, such as TNF-α, suggest the existence of a 
close correlation between PCT and pro-inflammatory cytokines, which earned him the name 
“ormokina” [82]. In the clinic, it was observed that there is a correlation between the timing of 
PCT, IL-6 and TNF-α. In acute inflammation, PCT values increase a few hours after the increase 
of IL-6 and TNF-α; at the end of the inflammation, the PCT begins to decrease after the decrease 
of the IL-6 and in any case before the CRP values start to decrease. This would demonstrate 
a pathophysiological function of PCT in the immune response. It would be responsible for 
increasing nitric oxide synthesis and monocyte migration to the site of infection [83].
6.6. Presepsin
Presepsin is another name for the sCD14 subtype (sCD14-ST), is a new biomarker associated 
with sepsis. Soluble CD14 subtype is one fragment of CD14 soluble that is a molecular fragment 
produced by plasma protease activity during the inflammatory process [84]. Presepsin is pres-
ent in the cell membranes of macrophages, monocytes and granulocyte cells and said to play 
a role for the intracellular transduction of endotoxin signals [85]. Presepsin has close relation 
with infection and is found to increase significantly in sepsis.
Behnes et al. showed that presepsin was moderately significant to determine between sepsis 
and non sepsis patient, with slightly overlapping value of 817.9 ± 572.7 and 294.2 ± 121.4 pg/
mL for sepsis and non sepsis patient, respectively [50]. The level of presepsin in serum usually 
raised within 2 h after infection and reach maximum level within 3 h, therefore it is useful in 
diagnosis of sepsis patient during early stages [86, 87].
Wu et al. reported a meta-analysis about diagnostic value of presepsin of some studies. The 
result showed that the sensitivity of presepsin ranged from 0.67 to 1.0, while the specificity 
of presepsin ranged from 0.33 to 0.98. The pooled sensitivity and specificity obtained by the 
HSROC method were 0.84 (95% CI 0.80–0.87) and 0.76 (95% CI 0.67–0.84), respectively. While 
ROC for presepsin showed the AUC was 0.88 (95% CI 0.85–0.90 [88].
When compared to PCT, presepsin showed similar diagnostic accuracy for sepsis with sensi-
tivity 0.78 [95% CI: 0.76–0.80] and 0.77 [95% CI: 0.72–0.81], specificity 0.83 [95% CI: 0.80–0.85] 
and 0.79 [95% CI: 0.74–0.84], AUCs 0.89 [95% CI: 0.84–0.94] and 0.85 [95% CI: 0.81–0.88], for 
presepsin and procalcitonin, respectively, to diagnose patient with sepsis and SIRS without 
infection [89].
However, there are some superiority of presepsin over PCT. Presepsin raised earlier in the 
event of infection therefore can be used in earlier and faster in sepsis. The PATHFAST analysis 
system also allow presepsin assay on takes 17 min to be done, therefore can be used accord-
ingly with the guidelines of diagnosis and treatment of sepsis.
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6.7. Bioadrenomedullin
Adrenomedullin (ADM) is a peptide with 52 amino acids initially isolated from the adrenal 
gland. It is produced in many organs and tissues including the vasculature. ADM has numer-
ous actions, including vasodilation, natriuresis, antiapoptosis and stimulation of NO produc-
tion. ADM is released from the vascular wall and acts as an autocrine or a paracrine hormone 
to regulate vascular tone and blood pressure. It may also be involved in the different stages of 
the cardiovascular continuum as well as in the hemodynamic changes in septic shock [90, 91].
A study by Crain et al. showed that in critically ill patients on admission, there was a stepwise 
increase in MR-proADM levels from patients without infection (e.g. SIRS) to patients with 
sepsis, severe sepsis and septic shock. Median proADM levels was 1.1 nmol/L (0.3–3.7 nmol/L) 
in patients with SIRS, 1.8 nmol/L (0.4–5.8 nmol/L) in patients with sepsis, 2.3 nmol/L (1.0–
17.6 nmol/L) in patients with severe sepsis and in patients with septic shock it was 4.5 nmol/L 
(0.9–21 nmol/L). There are two primary mechanisms that might be responsible for the marked 
increase in circulating MR-proADM and mature ADM levels in sepsis. The first mechanism, 
as a member of the CALC gene family, ADM is widely expressed and extensively synthe-
sized during sepsis, just like other calcitonin peptides including PCT, that upregulated by 
bacterial endotoxins and pro-inflammatory cytokines [92]. The second potential mechanism 
is the decreased clearance of MR-proADM by the kidneys in sepsis that may be responsible 
for its increased level. This hypothesis is also supported by a significant correlation between 
MR-proADM and creatinine levels (r = 0.76; P < 0.001). The study showed increase of plasma 
ADM five times higher that normal individuals, that did not changed after hemodialysis. An 
ideal sepsis marker should permit early diagnosis, should inform about the course of disease, 
and should help one to differentiate bacterial from non-infectious and viral causes of systemic 
inflammation [90].
Recently, the combined use of two biomarkers, procalcitonin (PCT) and mid-regional pro-
adrenomedullin (MR-proADM) has been reported in sepsis diagnosis and prognosis. In the 
last years, many articles have been published on the role of PCT and MR-proADM in the 
diagnosis and prognosis of bacterial infections in different settings. Angeletti et al. showed 
that MR-proADM differentiates sepsis from non-infectious systemic inflammatory response 
syndrome with high specificity and that the simultaneous measurement of MR-proADM and 
PCT in septic patients increases the post-test diagnostic probability compared to the inde-
pendent determination of individual markers. A score derived from the combination of PCT 
and MR-proADM has been recently proposed as a useful clinical tool to provide rapid diag-
nosis as well as to suggest prognosis of bacterial infections. The combined score, calculated 
on the basis of defined score assigned for each PCT and MR-proADM value, can predict bac-
terial infections and differentiate localized infections from systemic infections, as suggested 
by receiver operating characteristic curve analysis. On the basis of the score values, localized 
infections could be differentiated from systemic infections and the severity of the infectious 
disease can be predicted. The importance of the use of this multi-marker approach in the 
diagnosis and prognosis of sepsis is more evident since the publication of the new definition 
of sepsis that has been updated assigned an important role to the organ dysfunction [93].
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6.8. Comparison between biomarker of sepsis
Lactate should be evaluated at least within 24 h after emergency admission, the decrease 
of lactate after 24 h related to poor prognosis of the patients [94]. CRP can increase within 
24–48 h duration to 1000 folds during the acute phase and decrease to low normal value after 
the acute phase [95]. Procalcitonin start to rise 3–6 h after infection occur and reach its peak 
on 6–8 h, then remained in the blood until 12–48 h [96]. Meanwhile presepsin increase faster 
within 2–3 h after sepsis developed and rapidly decreased after symptoms resolved [97] so it 
can be used to determine whether the treatment is successful in patient with sepsis.
Several conditions can increase lactate in any person, such condition as inadequate oxygen 
delivery oxygen demands mismatch and inadequate oxygen utilization [94]. CRP increase 
in bacterial infection as part of innate immune response [95, 98]. It can also increase in condi-
tion of inflammation even can predict the cardiovascular event such as the sign of athero-
genesis and pathogenesis of myocardial injury and used as predictor in healthy individuals 
[99, 100]. It also can be a predictor of mortality in hemodialysis patient [101, 102]. Procalcitonin 
will rise in the event of sepsis, systemic infection and severe inflammation. Procalcitonin will not 
rise in the event of viral infection, autoimmune and neoplasma, but it can rise in some people with 
some neuroendocrine tumor such as medullare carcinoma of thyroid, small cell lung carcinoma 
and renal failure [96, 103]. Procalcitonin is also known to rise in person with trauma [97]. Some 
inflammation can trigger the rise of procalcitonin are pancreatitis [104], appendicitis [105], burns 
[106], heat stroke [107], multitrauma [108] and extensive surgery [109]. Presepsin do not increase 
in patient with trauma without associated infection, thus make it specific in patient with sepsis 
[97]. Presepsin also reliable in patient with sepsis and both acute kidney injury and those who do 
not, but it has caveats in patient with advanced kidney injury and end stage renal disease [110].
Head to head study by cochrane comparing procalcitonin, presepsin and CRP is still ongoing 
[111]. Several data about sensitivity and specificity of these parameters are already covered 
by some journal. The study about diagnostic value of lactate in cancer patient with sepsis 
showed for the cutoff value of lactate more than 1 mmol/L could predict sepsis with sensitiv-
ity of 86.36% and specificity of 28.12%, with additional data that the value were not differ-
ent in patient with and without cancer [112]. Another study showed 34.0% sensitivity and 
82.0% specificity at the cutoff point of 2.0 mmol/L that emphasized the low sensitivity but 
high specificity in diagnosing sepsis [113]. While other study measures prognostic value of 
lactate showed that lactate value over 4.0 mmol/L have increased mortality with sensitivity 
and specificity of 36 and 92%, respectively [114]. CRP found to be useful as part of screening 
in sepsis patient with sensitivity and specificity 98.5 and 75%, respectively, for cutoff value 
5 mg/dL or more [115]. Another study use CRP as parameter for successful treatment in ICU 
patient showed that decreasing level of CRP by 25% or more are good indicator with sensi-
tivity of 97% and specificity of 95% [116]. A study showed that sensitivity and specificity of 
procalcitonin were 75 and 79%, respectively [117]. While another study in patient with renal 
impairment proposed different cutoff to determine if patient is in septic condition, due to the 
caveats of procalcitonin in renal failure patient [118]. Another study comparing CRP, pro-
calcitonin and presepsin showed advantage of presepsin, with AUC of presepsin was 0.845, 
compared to PCT (0.652), and CRP (0.815). With sensitivity and specificity of presepsin with 
cutoff value 600 pg./mL was 87.8 and 81.4%, respectively [84].
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Availability and cost of these examination will be favored more on white blood cell count 
because it is part of routine practice everywhere, while for lactate, the difference between 
patient examined for lactate around $39.53/patient whereas the usual care cost $33.20/patient 
but the effectiveness in term of patient outcome and survival are better in those with lactate 
examination [119]. On the other hand, the use of CRP in England shows the use of CRP can 
also increase quality of treatment and decrease cost for patient which leads to fewer antibiotic 
prescriptions [120]. One study about procalcitonin use as part of management of patient with 
pneumonia find that procalcitonin although promising not significantly reduce cost of care, 
due to lack of data, since non adherence of the physician. This condition might be due to lack 
of experience of using procalcitonin and need for more guided protocol of procalcitonin use 
in patient [121].
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